Department of Anesthesia, Critical Care, and Pain Medicine, Massachusetts General Hospital, Boston, Massachusetts.
Johns Hopkins Institute for NanoBioTechnology (INBT), Baltimore, Maryland.
Pain Med. 2018 Feb 1;19(2):232-243. doi: 10.1093/pm/pnx131.
The objective of this article is to critically review both preclinical and clinical studies that focus on the use of nanotechnology for both acute and chronic pain management, surveying both diagnostic and therapeutic applications. The article also provides information on nanotechnology for pain practitioners, so that they may better understand how this technology works and how it may be applied to their day-to-day clinical practice.
Narrative review.
The Pubmed NCBI and EMBASE databases were utilized to review published reports of in vivo and clinical studies that focus on using nanotechnology for pain management applications in both the acute and chronic pain settings.
Articles were screened by title, abstract, and full article review. They were then analyzed by specific clinical indications, and appropriate data were presented based on a critical analysis of those articles.
As the development of nanomedical applications in acute and chronic pain management continues, medical practitioners should consider their growing potential to enhance the care of patients who are consistently living with pain. Current barriers to implementation include manufacturing scale-up for commercial viability, long-term nanoparticle toxicity considerations, and high cost for successful passage through clinical trials. These challenges will need to be overcome with ongoing translational research efforts in collaboration with industry and government bodies such as the Food and Drug Administration (FDA).
本文旨在对关注纳米技术在急性和慢性疼痛管理中的应用的临床前和临床研究进行批判性回顾,调查诊断和治疗应用。本文还为疼痛从业者提供了有关纳米技术的信息,以便他们更好地了解该技术的工作原理以及如何将其应用于日常临床实践。
叙述性综述。
利用 Pubmed NCBI 和 EMBASE 数据库,对关注纳米技术在急性和慢性疼痛环境中的疼痛管理应用的体内和临床研究报告进行了综述。
通过标题、摘要和全文审查筛选文章。然后根据对这些文章的批判性分析,按具体的临床适应证进行分析,并根据这些文章的批判性分析提出适当的数据。
随着纳米医学在急性和慢性疼痛管理中的应用的发展,医疗从业者应该考虑其在增强持续疼痛患者护理方面的潜在应用。目前实施的障碍包括商业化的制造规模扩大、长期纳米颗粒毒性考虑因素以及临床试验成功通过的高成本。这些挑战需要通过与工业界和政府机构(如食品和药物管理局(FDA))合作进行持续的转化研究来克服。